Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-06

REGENXBIO Inc. (RGNX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$4,200,712
Curran Simpson total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
92.25%
Say-on-pay support, latest vote
Companies that benchmark against RGNX
10 companies name RGNX as a compensation peer

Each company listed discloses RGNX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RGNX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Curran Simpson$665,510$0$777,448$2,350,302$387,327$0$20,125$4,200,712
President and Chief Executive Officer
Patrick Christmas520,903200,00001,096,810203,673020,1252,041,511
EVP, Chief Strategy and Legal Officer
Stephen Pakola543,9870505,343509,232220,859020,1251,799,546
EVP, Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Curran Simpson$4,200,712$4,784,543−583,831
Patrick Christmas2,041,5112,737,813−696,302
Stephen Pakola1,799,5462,696,858−897,312

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Stephen PakolaChief Medical Officer2026-05-11D15,309$11$168,705Common, open-market saleForm 4 ↗
Jean BennettDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
Kenneth T. MillsDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
David C. StumpDirector2026-05-29A9,80700CommonForm 4 ↗
Jennifer ZacharyDirector2026-05-29A9,80700CommonForm 4 ↗
Jennifer ZacharyDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
George MigauskyDirector2026-05-29A9,80700CommonForm 4 ↗
George MigauskyDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
A.N. Jerry KarabelasDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
Jean BennettDirector2026-05-29A9,80700CommonForm 4 ↗
Alexandra GlucksmannDirector2026-05-29A9,80700CommonForm 4 ↗
Alexandra GlucksmannDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
Kenneth T. MillsDirector2026-05-29A9,80700CommonForm 4 ↗
Allan M. FoxDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
Daniel TasseDirector2026-05-29A9,80700CommonForm 4 ↗
Daniel TasseDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
David C. StumpDirector2026-05-29A46,60000Derivative, Class A CommonForm 4 ↗
Allan M. FoxDirector2026-05-29A9,80700CommonForm 4 ↗
A.N. Jerry KarabelasDirector2026-05-29A9,80700CommonForm 4 ↗
Stephen PakolaChief Medical Officer2026-06-29D19,60811216,472Common, open-market saleForm 4 ↗
Stephen PakolaChief Medical Officer2026-06-29D36,72513472,284CommonForm 4 ↗
Stephen PakolaChief Medical Officer2026-06-29D36,72500Derivative, Class A CommonForm 4 ↗
Stephen PakolaChief Medical Officer2026-06-29A36,7258288,659CommonForm 4 ↗
Stephen PakolaChief Medical Officer2026-07-02A2,161816,985CommonForm 4 ↗
Stephen PakolaChief Medical Officer2026-07-02D2,16100Derivative, Class A CommonForm 4 ↗
Stephen PakolaChief Medical Officer2026-07-02D2,1611429,476CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Curran SimpsonOPTION$2,350,302
Curran SimpsonRSU777,448
Stephen PakolaRSU505,343
Stephen PakolaOPTION509,232
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Curran Simpson$777,448$0$2,350,3020.0%
Stephen Pakola505,3430509,2320.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Curran SimpsonRSU98,912$1,424,333
Patrick ChristmasRSU28,223406,411
Stephen PakolaOption88534.31
Stephen PakolaOption103,6987.86
Stephen PakolaRSU2,22532,040
Curran SimpsonRSU28,846415,382
Patrick ChristmasOption28,61718.34
Stephen PakolaRSU64,293925,819
Stephen PakolaOption11,95922.25
Curran SimpsonOption478,6067.86
Stephen PakolaRSU29,193420,379
Curran SimpsonRSU33,972489,197
Patrick ChristmasRSU25,961373,838
Curran SimpsonOption14,35022.25
Curran SimpsonOption175,78911.07
Patrick ChristmasOption77934.31
Stephen PakolaOption26,49718.34
Patrick ChristmasOption15,30722.25
Patrick ChristmasOption223,3507.86
Curran SimpsonOption1,06534.31
Stephen PakolaRSU45,294652,234
Patrick ChristmasRSU1,97528,440
Stephen PakolaRSU24,038346,147
Curran SimpsonOption31,79718.34
Patrick ChristmasRSU33,970489,168
Curran SimpsonRSU42,343609,739
Curran SimpsonRSU2,67538,520
05

Incentive-plan design — the Compensation Discussion & Analysis

Our Compensation Committee and Board seek to establish and maintain base salaries for each position and level of responsibility that are competitive with those of executives at our peer group companies.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantWillis Towers Watson
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2932,392,3022,722,825149,63592.25%Passed
20252025-05-3032,577,6031,756,15593,78794.89%Passed
20242024-05-3140,147,111727,84635,36298.22%Passed
20232023-06-0236,733,3451,131,884111,32197.01%Passed
20222022-06-0335,342,7311,197,53437,11996.72%Passed
20212021-06-0434,872,771789,01129,95597.79%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2992.25%a
20252025-05-3094.89%b
20242024-05-3198.22%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted "For" or "Against" Proposal 3, Proposal 4 or Proposal 5 and will have no effect on the outcome of either proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of the proposal.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted "For" or "Against" Proposal 2 or Proposal 3 and will have no effect on the outcome of either proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Daniel TassIndependent · Lead Independent Director · Compensation (Chair)$85,000$68,747$206,247$0$0$359,994
Kenneth T. MillsNot independent · Board Chair80,00068,747206,24700354,994
George MigauskyIndependent · Audit (Chair)65,00068,747206,24700339,994
David C. StumpIndependent · Audit · Nominating/Governance (Chair)65,00068,747206,24700339,994
Jennifer ZacharyIndependent · Audit55,00068,747206,24700329,994
Alexandra GlucksmannIndependent · Compensation52,50068,747206,24700327,494
A.N. Jerry KarabelasIndependent · Compensation52,50068,747206,24700327,494
Jean BennettIndependent · Nominating/Governance50,00068,747206,24700324,994
Allan M. FoxIndependent · Nominating/Governance45,00068,747206,24700319,994
Curran SimpsonEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$275,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$550,000
Equity awards (grant-date value)$618,723
All other compensation$0
Total cost of the board$1,168,723

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1REGENXBIO Inc.2025Curran Simpson$665,510$777,448$2,350,302$387,327$4,200,712

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

FAQ

Frequently asked questions

Who was the highest-paid executive at REGENXBIO Inc. in fiscal 2025?
The highest-paid executive at REGENXBIO Inc. in fiscal 2025 was Curran Simpson, who served as President and Chief Executive Officer with total compensation of $4,200,712.
How does REGENXBIO Inc.'s chief executive pay compare to its disclosed peer group?
The filing shows that the CEO-to-median employee pay ratio was not disclosed, and the CEO pay percentile of disclosed peers was not disclosed in this extract.
What is REGENXBIO Inc.'s CEO-to-median employee pay ratio?
The filing shows that the CEO-to-median employee pay ratio was not disclosed, and the CEO pay percentile of disclosed peers was not disclosed in this extract.
How did shareholders vote on REGENXBIO Inc.'s executive compensation?
Shareholders supported the executive compensation plan with 92.25% approval in the latest vote.
How much does REGENXBIO Inc. spend in total on board compensation for fiscal 2025?
The company reported total board compensation for fiscal 2025 as $1,168,723.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Curran SimpsonDEF 14A2026-04-140001193125-26-155058Section “Summary Compensation Table”. As printed: 4,200,712. Filing ↗machine: r2 · c16 · span 436444–436453
2Section 01, Patrick ChristmasDEF 14A2026-04-140001193125-26-155058Section “Summary Compensation Table”. As printed: 2,041,511. Filing ↗machine: r8 · c16 · span 470187–470196
3Section 01, Stephen PakolaDEF 14A2026-04-140001193125-26-155058Section “Summary Compensation Table”. As printed: 1,799,546. Filing ↗machine: r5 · c16 · span 453321–453330
4Section 03, Curran Simpson OPTIONDEF 14A2026-04-140001193125-26-155058Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c10 · span 434503–434512
5Section 03, Curran Simpson RSUDEF 14A2026-04-140001193125-26-155058Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c8 · span 433862–433869
6Section 03, Stephen Pakola RSUDEF 14A2026-04-140001193125-26-155058Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t12 · r5 · c8 · span 450741–450748
7Section 03, Stephen Pakola OPTIONDEF 14A2026-04-140001193125-26-155058Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t12 · r5 · c10 · span 451382–451389
8Section 07, pay ratio10-K2026-03-050001193125-26-094013Section “CEO Pay Ratio”. As printed: —. Filing ↗
9Section 08, Daniel TassDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 359,994. Filing ↗
10Section 08, Kenneth T. MillsDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 354,994. Filing ↗machine: t8 · r7 · c8 · span 330327–330334
11Section 08, George MigauskyDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 339,994. Filing ↗machine: t8 · r6 · c8 · span 327251–327258
12Section 08, David C. StumpDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 339,994. Filing ↗machine: t8 · r8 · c8 · span 333407–333414
13Section 08, Jennifer ZacharyDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 329,994. Filing ↗machine: t8 · r10 · c8 · span 339560–339567
14Section 08, Alexandra GlucksmannDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 327,494. Filing ↗machine: t8 · r4 · c8 · span 321075–321082
15Section 08, A.N. Jerry KarabelasDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 327,494. Filing ↗machine: t8 · r5 · c8 · span 324176–324183
16Section 08, Jean BennettDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 324,994. Filing ↗machine: t8 · r2 · c8 · span 314916–314923
17Section 08, Allan M. FoxDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 319,994. Filing ↗machine: t8 · r3 · c8 · span 317988–317995
18Section 08, Curran SimpsonDEF 14A2026-04-140001193125-26-155058Section “Director Compensation”. As printed: 0. Filing ↗
19Section 02, Stephen Pakola 2026-05-11Form 42026-05-130001700659-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Jean Bennett 2026-05-29Form 42026-06-020001872219-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Kenneth T. Mills 2026-05-29Form 42026-06-020001652824-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, David C. Stump 2026-05-29Form 42026-06-020001191235-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Jennifer Zachary 2026-05-29Form 42026-06-020001737231-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Jennifer Zachary 2026-05-29Form 42026-06-020001737231-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, George Migausky 2026-05-29Form 42026-06-020001134365-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, George Migausky 2026-05-29Form 42026-06-020001134365-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, A.N. Jerry Karabelas 2026-05-29Form 42026-06-020001191229-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Jean Bennett 2026-05-29Form 42026-06-020001872219-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Alexandra Glucksmann 2026-05-29Form 42026-06-020001658390-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Alexandra Glucksmann 2026-05-29Form 42026-06-020001658390-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Kenneth T. Mills 2026-05-29Form 42026-06-020001652824-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Allan M. Fox 2026-05-29Form 42026-06-020001652936-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Daniel Tasse 2026-05-29Form 42026-06-020001502785-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Daniel Tasse 2026-05-29Form 42026-06-020001502785-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, David C. Stump 2026-05-29Form 42026-06-020001191235-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Allan M. Fox 2026-05-29Form 42026-06-020001652936-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, A.N. Jerry Karabelas 2026-05-29Form 42026-06-020001191229-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Stephen Pakola 2026-06-29Form 42026-07-010001700659-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Stephen Pakola 2026-06-29Form 42026-07-010001700659-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Stephen Pakola 2026-06-29Form 42026-07-010001700659-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Stephen Pakola 2026-06-29Form 42026-07-010001700659-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Stephen Pakola 2026-07-02Form 42026-07-060001700659-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Stephen Pakola 2026-07-02Form 42026-07-060001700659-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Stephen Pakola 2026-07-02Form 42026-07-060001700659-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
45Section 06, 2026 voteForm 8-K2026-06-030001193125-26-254590Item 5.07 · say-on-pay result. As reported: 92.25% (votes for as printed: 32,392,302). Filing ↗
46Section 06, 2025 voteForm 8-K2025-06-030000950170-25-080986Item 5.07 · say-on-pay result. As reported: 94.89% (votes for as printed: 32,577,603). Filing ↗
47Section 06, 2024 voteForm 8-K2024-06-030000950170-24-068050Item 5.07 · say-on-pay result. As reported: 98.22% (votes for as printed: 40,147,111). Filing ↗
48Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
49Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
50Section 09b board cost (computed)ComputedcomputedCash 550,000 + equity 618,723 + all other 0 = 1,168,723, summed across the director compensation table rows.machine: formula: Σ = 1,168,723
51REGENXBIO Inc. (subject), Section 10b CEO totalDEF 14A2026-04-140001193125-26-155058CEO total compensation as printed in REGENXBIO Inc.'s own proxy. As printed: 4,200,712. Filing ↗machine: r2 · c16 · span 436444–436453